This study evaluates pharmacogenomic variants in CYP2C19, CYP2D6, and VKORC1 as predictors of adverse drug reactions in 3,200 patients receiving cardiovascular medications, demonstrating significant clinical utility.
Keywords: Pharmacogenomics, Adverse Drug Reactions, Cardiovascular, CYP2C19, Personalized Medicine